EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial

Takahiro Iijima iD, Makoto Shibuya, Yuzuru Ito, Yasuo Terauchi

Journal of Diabetes Investigation · 2023

DOI: 10.1111/jdi.14000 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes Investigation, 2023. Verfasst von Takahiro Iijima und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Few studies have examined the effects of glucagon‐like peptide‐1 receptor agonist switching, particularly in Japanese patients. Therefore, we aimed to investigate the effects of switching from liraglutide to semaglutide or dulaglutide on blood glucose, body weight, and the occurrence of adverse effects in clinical practice. Materials and Methods This was an open‐label, prospective, randomized, parallel‐group controlled trial. Patients with type 2 diabetes treated with liraglutide (0.6 or 0.9 mg) at Yokosuka Kyosai Hospital in Japan were recruited from September 2020 to March 2022 and, after obtaining informed consent, randomly assigned to the semaglutide or dulaglutide group (1:1). Changes in the glycated hemoglobin level from baseline to weeks 8, 16, and 26 were evaluated post‐treatment.

Results

Initially, 32 participants were enrolled, of whom 30 completed the study. Glycemic control was significantly better in the semaglutide group than in the dulaglutide group (−0.42 ± 0.49% vs −0.00 ± 0.34%, P = 0.0120). Body weight significantly decreased in the semaglutide group (−2.6 ± 3.6 kg, P = 0.0153), whereas no change was observed in the dulaglutide group (−0.1 ± 2.7 kg, P = 0.8432). We found a significant difference in body weight between the groups ( P = 0.0469). The proportion of participants who reported adverse events was 75.0% and 18.8% in the semaglutide and dulaglutide groups, respectively. One patient in the semaglutide group had difficulty continuing treatment due to severe vomiting and weight loss.

Conclusions

Switching from once‐daily liraglutide to once‐weekly semaglutide 0.5 mg significantly improved glycemic control and body weight compared with switching to once‐weekly dulaglutide 0.75 mg.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansLiraglutideHypoglycemic AgentsProspective StudiesGlycated HemoglobinRecombinant Fusion ProteinsBody WeightSemaglutideGlucagon-Like PeptidesImmunoglobulin Fc Fragments

Stichwörter der Autor:innen

Diabetes mellitusDulaglutideSemaglutide

Substanzen

LiraglutideHypoglycemic AgentsGlycated HemoglobinRecombinant Fusion ProteinsSemaglutidedulaglutideGlucagon-Like PeptidesImmunoglobulin Fc Fragments

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Department of Endocrinology, Diabetes and Metabolism, Yokosuka Kyosai Hospital, Yokosuka, Japan.
  • Yuzuru Clinic, Saitama, Japan.

ORCID-Profile: Takahiro Iijima

Zitieren

APA

Iijima, T., Shibuya, M., Ito, Y., & Terauchi, Y. (2023). Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14000

Vancouver

Iijima T, Shibuya M, Ito Y, Terauchi Y. Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial. Journal of Diabetes Investigation. 2023. doi:10.1111/jdi.14000

BibTeX
@article{Iijima2023,
  author = {Iijima, Takahiro and Shibuya, Makoto and Ito, Yuzuru and Terauchi, Yasuo},
  title = {Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial},
  journal = {Journal of Diabetes Investigation},
  year = {2023},
  doi = {10.1111/jdi.14000}
}
Kostenlos starten →